Pharmacokinetics and Safety of Gadobenate Dimeglumine (Multihance) in Subjects With Impaired Liver Function

Abstract

Hepatic impairment did not modify the pharmacokinetics of gadobenate dimeglumine compared with values reported elsewhere for healthy subjects. The contrast agent was well tolerated and safe with an overall incidence of adverse events comparable to that of placebo.